NEW YORK, Nov. 14, 2017 /PRNewswire/ --If you want a Stock Review on ONVO, BEAT, BRKR, or PKI then come over to http://dailystocktracker.com/register/and sign up for your free customized report. On Monday, November 13, 2017, US markets saw four out of nine sectors finishing the day in red, two in green, and three in neutral territory. Major US indices were also bullish
On Monday, shares in San Diego, California headquartered Organovo Holdings Inc. recorded a trading volume of 928,427 shares. The stock ended the session 7.79% lower at $1.42. The stock is trading below its 50-day moving averages by 22.79%. Moreover, shares of Organovo, which designs and creates functional and three-dimensional human tissues for use in medical research and therapeutic applications, have a Relative Strength Index (RSI) of 36.81.
On November 10th, 2017, research firm Raymond James downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Visit us today and download your complete report on ONVO for free at:
Malvern, Pennsylvania headquartered BioTelemetry Inc.'s stock closed the day 6.38% higher at $25.85 with a total trading volume of 825,704 shares, which was above their three months average volume of 557.87 thousand shares. The Company's shares have advanced 41.26% over the last twelve months and 15.66% since the start of this year. The stock is trading below its 50-day moving average by 18.93%. Additionally, shares of BioTelemetry, which provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services, have an RSI of 33.19.
On November 08th, 2017, research firm Dougherty & Company reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $35 a share to $40 a share. The complimentary research report on BEAT can be accessed at:
Shares in Billerica, Massachusetts headquartered Bruker Corp. recorded a trading volume of 657,715 shares, which was above their three months average volume of 504.37 thousand shares. The stock ended yesterday's trading session 1.76% higher at $32.39. The Company's shares have advanced 16.80% over the previous three months, 41.63% in the past twelve months, and 52.93% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.34% and 19.56%, respectively. Furthermore, shares of Bruker, which develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide, have an RSI of 58.88.
On November 03rd, 2017, research firm JP Morgan upgraded the Company's stock rating from 'Underweight' to 'Neutral'. Register for free on DailyStockTracker.com and download the research report on BRKR at:
Waltham, Massachusetts headquartered PerkinElmer Inc.'s stock finished Monday's session 0.08% lower at $71.27 with a total trading volume of 491,241 shares. The Company's shares have advanced 11.12% over the previous three months, 40.02% in the past twelve months, and 36.66% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.72% and 12.16%, respectively. Additionally, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have an RSI of 51.44. Get free access to your research report on PKI at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/medical-research-stocks-on-investors-radar----organovo-biotelemetry-bruker-and-perkinelmer-300555434.html
Subscribe to our Free Newsletters!
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...View All